Qiming Venture Partners Investors Land on ChinaVenture 2025 Investor Rankings

Recently, the ChinaVenture 2025 Annual Investors Ranking was officially released. For 19 consecutive years, ChinaVenture has published this series of rankings for China's venture capital and private equity investment institutions as an independent third-party organization. Drawing on ChinaVenture Jiachuan CVSource data and surveys of over 1,000 active investment institutions in the private equity space, the ChinaVenture research team reviews data against selection criteria to identify top performers. As a result, the "ChinaVenture Ranking" is widely recognized in the industry for its professionalism, authority, and rigor — considered a bellwether for China's equity investment industry and an important reference for major institutional LPs when making capital commitments.

Duane Kuang, Founding Managing Partner of Qiming Venture Partners; William Hu and Alex Zhou, Managing Partners; and Kan Chen, Partner and Co-Head of Healthcare Innovation, were named to the China Top 100 Best Venture Capitalists. Thomas Yeh, Partner at Qiming Venture Partners, was named a China Best Investment Return Investor.

Duane Kuang, Founding Managing Partner of Qiming Venture Partners

William Hu, Managing Partner of Qiming Venture Partners

Alex Zhou, Managing Partner of Qiming Venture Partners

Kan Chen, Partner and Co-Head of Healthcare Innovation at Qiming Venture Partners

Awarded

China Top 100 Best Venture Capitalists

Thomas Yeh, Partner at Qiming Venture Partners

Awarded

China Best Investment Return Investor

Selection Criteria

ChinaVenture 2025 Annual Investors Ranking Evaluation Standards

The ranking uses quantitative metrics from the three-year period of July 1, 2022 to June 30, 2025, including the number and value of investment cases, the number and value of exits, performance results, and valuations of portfolio companies. Based on these quantitative assessments, candidates are shortlisted. A qualitative evaluation is then conducted through questionnaire surveys, after which candidates are ranked by score. The final Best Investors list incorporates IPO exit data from July 1, 2025 to December 29, 2025.

ChinaVenture 2025 China Best Investment Return Investor

Selection criteria: Ranking is based on individual projects where cumulative exit value (net of cumulative investment cost) exceeded $1 billion or approximately RMB 7 billion during the period of July 1, 2022 to December 29, 2025.

ChinaVenture noted that in 2025, A-share IPOs maintained a steady overall pace while showing significant improvement in quality. The semiconductor and AI sectors became prime wealth-generating grounds for new listings. As national policies continue to boost technological innovation and the AI industry experiences full-scale growth, amplified by the demonstration effect of leading companies repeatedly hitting new highs in the capital markets, investors are re-evaluating enterprises with core competitive advantages through a fresh lens. The convergence of technological transformation and independent innovation has given domestic investors a gift of the era.

Source | ChinaVenture

Past Highlights

Qiming Honors | Qiming Venture Partners Ranks 5th in Zero2IPO's 2024 China Venture Capital Institutions Ranking, Among Five Awards Qiming Honors | Qiming Venture Partners and Its Investors Win Shanghai Securities News 2025 "Golden Eagle · Financial Capital" Awards Qiming Honors | Qiming Venture Partners Wins Three Awards at China Venture Capital Research Institute's 2025 China Venture Capital Industry Annual Golden Investment Awards

Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare Innovation.

To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies. More than 210 of these have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.

Many companies in Qiming Venture Partners' portfolio have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ: HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ: WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Insilico Medicine (03696.HK), Hoba Therapeutics, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, and others.